Innovent and Ask Biopharma Receives China’s NMPA Approval for Limertinib to Treat Non-Small Cell Lung Cancer
Shots:
- NMPA approved limertinib (oral EGFRm TKI) to treat LA/M EGFR T790M-mutated NSCLC in adults, based P-IIb trial assessing limertinib in (n=301) NSCLC patients
- This study showed 68.8% ORR, 92.4% DCR, plus 11mos. mPFS with 11.1mos. mDoR. It also showed ORR & mPFS of 65.9% & 10.6mos., respectively in patients with assessable CNS lesions with favourable safety.
- Additionally, a P-III trial assessing limertinib vs gefitinib as 1L therapy of LA/M EGFRm+ NSCLC met its 1EP, results of which will be reported at upcoming conferences or publications. Another NDA for LA/M EGFR 19DEL+ or L858R+ NSCLC is under NMPA review
Ref: Innovent & Ask Biopharma | Image: Innovent & Ask Biopharma
Related News:- Innovent’s IBI343 Secures the NMPA’s Breakthrough Therapy Designation for Advanced Pancreatic Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
